Asthika Goonewardene
Stock Analyst at Truist Securities
(1.15)
# 3,433
Out of 4,749 analysts
89
Total ratings
31.65%
Success rate
-14.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRGX CARGO Therapeutics | Downgrades: Hold | $32 → $7 | $3.55 | +97.46% | 3 | Jan 30, 2025 | |
| EXEL Exelixis | Maintains: Buy | $42 → $43 | $33.60 | +27.97% | 8 | Jan 27, 2025 | |
| IGMS IGM Biosciences | Maintains: Hold | $12 → $2 | $1.51 | +32.89% | 8 | Jan 10, 2025 | |
| BNTX BioNTech SE | Initiates: Buy | $172 | $124.52 | +38.14% | 1 | Jan 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $35 | $22.08 | +58.55% | 1 | Jan 8, 2025 | |
| ACLX Arcellx | Maintains: Buy | $87 → $136 | $69.61 | +95.37% | 5 | Nov 12, 2024 | |
| GILD Gilead Sciences | Maintains: Hold | $83 → $97 | $98.11 | -1.13% | 1 | Nov 8, 2024 | |
| GMAB Genmab | Maintains: Buy | $53 → $50 | $19.93 | +150.88% | 13 | Sep 9, 2024 | |
| STRO Sutro Biopharma | Maintains: Buy | $18 → $15 | $2.00 | +648.50% | 6 | Aug 16, 2024 | |
| ALLO Allogene Therapeutics | Reiterates: Buy | $17 → $14 | $1.91 | +634.91% | 6 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $44 | $13.34 | +229.84% | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $88 | $37.82 | +132.68% | 1 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $69 → $88 | $41.65 | +111.31% | 2 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $2.37 | +68.78% | 5 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 | $1.53 | +1,145.90% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $26 | $6.04 | +330.58% | 5 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.62 | +1,341.15% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $2.07 | +1,837.05% | 4 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $27 | $0.89 | +2,935.41% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $9 | $2.25 | +300.89% | 3 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Hold | $120 | $23.55 | +409.55% | 1 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $100 → $60 | $2.09 | +2,770.13% | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $0.80 | +1,764.51% | 4 | Aug 23, 2022 |
CARGO Therapeutics
Jan 30, 2025
Downgrades: Hold
Price Target: $32 → $7
Current: $3.55
Upside: +97.46%
Exelixis
Jan 27, 2025
Maintains: Buy
Price Target: $42 → $43
Current: $33.60
Upside: +27.97%
IGM Biosciences
Jan 10, 2025
Maintains: Hold
Price Target: $12 → $2
Current: $1.51
Upside: +32.89%
BioNTech SE
Jan 10, 2025
Initiates: Buy
Price Target: $172
Current: $124.52
Upside: +38.14%
Summit Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $35
Current: $22.08
Upside: +58.55%
Arcellx
Nov 12, 2024
Maintains: Buy
Price Target: $87 → $136
Current: $69.61
Upside: +95.37%
Gilead Sciences
Nov 8, 2024
Maintains: Hold
Price Target: $83 → $97
Current: $98.11
Upside: -1.13%
Genmab
Sep 9, 2024
Maintains: Buy
Price Target: $53 → $50
Current: $19.93
Upside: +150.88%
Sutro Biopharma
Aug 16, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $2.00
Upside: +648.50%
Allogene Therapeutics
Aug 9, 2024
Reiterates: Buy
Price Target: $17 → $14
Current: $1.91
Upside: +634.91%
Jun 24, 2024
Maintains: Buy
Price Target: $50 → $44
Current: $13.34
Upside: +229.84%
Jun 17, 2024
Initiates: Buy
Price Target: $88
Current: $37.82
Upside: +132.68%
Jun 4, 2024
Maintains: Buy
Price Target: $69 → $88
Current: $41.65
Upside: +111.31%
May 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $2.37
Upside: +68.78%
May 16, 2024
Maintains: Buy
Price Target: $19
Current: $1.53
Upside: +1,145.90%
Mar 7, 2024
Maintains: Buy
Price Target: $17 → $26
Current: $6.04
Upside: +330.58%
Feb 29, 2024
Upgrades: Buy
Price Target: $9
Current: $0.62
Upside: +1,341.15%
Sep 6, 2023
Reiterates: Buy
Price Target: $40
Current: $2.07
Upside: +1,837.05%
Sep 6, 2023
Reiterates: Buy
Price Target: $27
Current: $0.89
Upside: +2,935.41%
Aug 17, 2023
Maintains: Buy
Price Target: $6 → $9
Current: $2.25
Upside: +300.89%
Apr 5, 2023
Reinstates: Hold
Price Target: $120
Current: $23.55
Upside: +409.55%
Aug 23, 2022
Maintains: Hold
Price Target: $100 → $60
Current: $2.09
Upside: +2,770.13%
Aug 23, 2022
Maintains: Buy
Price Target: $19 → $15
Current: $0.80
Upside: +1,764.51%